Track topics on Twitter Track topics that are important to you
On Mar 21, 2019, Biogen announced that the anti-amyloid antibody aducanumab failed futility analyses in two identically designed phase 3 Alzheimer's disease trials, and discontinued its development. However, on Oct 22, 2019, Biogen made the surprise announcement that they were applying for US Food and Drug Administration (FDA) marketing approval of aducanumab. The company explained that they reanalysed data from the trials to include patients who had continued in the studies from the Dec 26, 2018, cut-off date for the futility analyses to Mar 21, 2019, when futility was announced.
Original Article: [In Context] A resurrection of aducanumab for Alzheimer's diseaseNEXT ARTICLE
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase 'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...